PL365012A1 - Antybiotyki makrolidowe - Google Patents

Antybiotyki makrolidowe

Info

Publication number
PL365012A1
PL365012A1 PL01365012A PL36501201A PL365012A1 PL 365012 A1 PL365012 A1 PL 365012A1 PL 01365012 A PL01365012 A PL 01365012A PL 36501201 A PL36501201 A PL 36501201A PL 365012 A1 PL365012 A1 PL 365012A1
Authority
PL
Poland
Prior art keywords
macrolide antibiotics
macrolide
antibiotics
Prior art date
Application number
PL01365012A
Other languages
English (en)
Inventor
Daniele Andreotti
Luca Arista
Stefano Biondi
Francesca Cardullo
Frederica Damiani
Sergio Lociuro
Carla Marchioro
Giancarlo Merlo
Anna Mingardi
Daniela Niccolai
Alfredo Paio
Elisabetta Piga
Alfonso Pozzan
Catia Seri
Luca Tarsi
Silvia Terreni
Jessica Tibasco
Sulejman Alihodzic
Manuela Ciraco
Original Assignee
Glaxo Group Limited
Pliva -Istrazivacki Institut D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0031309A external-priority patent/GB0031309D0/en
Priority claimed from GB0126277A external-priority patent/GB0126277D0/en
Priority claimed from GB0126276A external-priority patent/GB0126276D0/en
Application filed by Glaxo Group Limited, Pliva -Istrazivacki Institut D.O.O. filed Critical Glaxo Group Limited
Publication of PL365012A1 publication Critical patent/PL365012A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL01365012A 2000-12-21 2001-12-20 Antybiotyki makrolidowe PL365012A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0031309A GB0031309D0 (en) 2000-12-21 2000-12-21 Macrolides
GB0126277A GB0126277D0 (en) 2001-11-01 2001-11-01 Macrolides
GB0126276A GB0126276D0 (en) 2001-11-01 2001-11-01 Macolides

Publications (1)

Publication Number Publication Date
PL365012A1 true PL365012A1 (pl) 2004-12-27

Family

ID=27256023

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365012A PL365012A1 (pl) 2000-12-21 2001-12-20 Antybiotyki makrolidowe

Country Status (20)

Country Link
US (3) US20040077557A1 (pl)
EP (1) EP1363925B8 (pl)
JP (1) JP2004531471A (pl)
KR (1) KR20030068189A (pl)
CN (1) CN1492874A (pl)
AR (1) AR042583A1 (pl)
AT (1) ATE345350T1 (pl)
AU (2) AU1727702A (pl)
BR (1) BR0116431A (pl)
CA (1) CA2432429A1 (pl)
CZ (1) CZ20031751A3 (pl)
DE (1) DE60124594T2 (pl)
ES (1) ES2275621T3 (pl)
HU (1) HUP0302526A2 (pl)
IL (1) IL156561A0 (pl)
MX (1) MXPA03005668A (pl)
NO (1) NO20032846L (pl)
NZ (1) NZ526450A (pl)
PL (1) PL365012A1 (pl)
WO (1) WO2002050091A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US6995143B2 (en) * 2002-02-28 2006-02-07 Basilea Pharmaceutica Ag Macrolides with antibacterial activity
US6727229B2 (en) 2002-08-19 2004-04-27 Enanta Pharmaceuticals, Inc. 11,12-substituted lactone ketolide derivatives having antibacterial activity
US6720308B1 (en) 2002-11-07 2004-04-13 Enanta Pharmaceuticals, Inc. Anhydrolide derivatives having antibacterial activity
HRP20020886A2 (en) * 2002-11-11 2005-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. SUBSTITUTED 9a-N-[N'-(BENZENSULFONYL)CARBAMOYL-γ-AMINOPROPYL) AND 9a-N(N' -(?-CYANOETHIL)-N' -(b
HRP20020991A2 (en) * 2002-12-12 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. N"-Substituted 9a-N-(N'-carbamoyl-Gamma-aminopropyl), 9a-N-(N'? -thiocarbamoyl-Gamma-aminopropyl), 9a-N-(N'-((Beta-cyanoethyl)-N'-carbamoyl-Gamma? -aminopropyl) and 9a-N-(N'-(Beta-cyanoethyl)-N'-thiocarbamoyl-Gamma? -aminopropyl) derivatives of 9-de
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
US6790835B1 (en) 2003-06-05 2004-09-14 Enanta Pharmaceuticals, Inc. Bicyclic macrolide derivatives
US6716820B1 (en) 2003-06-05 2004-04-06 Enanta Pharmaceuticals, Inc. 6-O-substituted bicyclic macrolides
US6765016B1 (en) 2003-06-05 2004-07-20 Enanta Pharmaceuticals, Inc. Bicyclic ketolide derivatives
US6774115B1 (en) 2003-06-05 2004-08-10 Enanta Pharmaceuticals, Inc. 6-O-substituted bicyclic ketolides
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
US7253164B2 (en) * 2003-07-31 2007-08-07 Irm Llc Bicyclic compounds and compositions as PDF inhibitors
DE602004004156T2 (de) 2003-08-20 2007-10-11 Eli Lilly And Co., Indianapolis Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids
MXPA06001916A (es) * 2003-08-20 2006-05-17 Lilly Co Eli Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
RU2403237C2 (ru) * 2004-05-14 2010-11-10 Эмисфире Текнолоджис, Инк. Составы и смеси для доставки активных агентов
EP1836211B1 (en) * 2004-12-21 2010-03-03 Pfizer Products Inc. Macrolides
CN101115764B (zh) * 2005-02-09 2012-09-26 巴斯利尔药物股份公司 大环内酯类化合物
EP1879903A1 (en) 2005-05-10 2008-01-23 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Ether linked macrolides useful for the treatment of microbial infections
WO2007105581A1 (ja) * 2006-03-10 2007-09-20 Yuuzou Tsuchida 抗微生物剤及び抗微生物性組成物
US8124744B2 (en) * 2006-05-01 2012-02-28 Taisho Pharmaceutical Co., Ltd. Macrolide derivatives
WO2008023248A2 (en) 2006-08-24 2008-02-28 Wockhardt Research Centre Novel macrolides and ketolides having antimicrobial activity
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
AU2007299870A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
CA2672776A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010025436A2 (en) * 2008-08-29 2010-03-04 Triad Multitech Pharmaceuticals, Inc. Nitrogen and sulfur-containing heterocycle derivatives
BRPI1011959A2 (pt) 2009-05-27 2016-04-26 Wockhardt Research Center compostos de cetolídeo tendo atividade antimicrobiana.
WO2012008549A1 (ja) 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
CN102417530A (zh) * 2010-09-26 2012-04-18 中国医学科学院药物研究所 广谱抗菌素红霉素a大环酮内酯类衍生物的合成方法和用途
PL2673285T3 (pl) 2010-12-09 2017-12-29 Wockhardt Limited Związki ketolidowe
JP5718488B2 (ja) * 2011-03-01 2015-05-13 ウォックハート リミテッド ケトライド中間体の調製方法
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20160061743A (ko) 2014-11-24 2016-06-01 주식회사 엘지화학 고흡수성 수지 및 이의 제조 방법
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN110272417B (zh) * 2019-06-18 2021-07-13 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用
KR20220113431A (ko) 2019-12-02 2022-08-12 스톰 테라퓨틱스 리미티드 Mettl3 저해제로서의 폴리헤테로환식 화합물
US11999703B1 (en) 2023-10-25 2024-06-04 King Faisal University 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732684B1 (fr) * 1995-04-06 1997-04-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP2004514643A (ja) * 1997-10-29 2004-05-20 大正製薬株式会社 エリスロマイシンａ誘導体
AU9649598A (en) * 1997-10-29 1999-05-17 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
BR9916969A (pt) * 1999-01-27 2001-11-06 Pfizer Prod Inc Antibióticos cetólidos
US6355620B1 (en) * 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
EP1114826A3 (en) * 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
WO2002016380A1 (en) * 2000-08-22 2002-02-28 Basilea Pharmaceutica Ag New macrolides with antibacterial activity
WO2003024986A1 (en) * 2001-09-17 2003-03-27 Ortho-Mcneil Pharmaceutical, Inc. 6-o-carbamate-11,12-lacto-ketolide antimicrobials

Also Published As

Publication number Publication date
HUP0302526A2 (hu) 2003-11-28
WO2002050091A1 (en) 2002-06-27
KR20030068189A (ko) 2003-08-19
EP1363925B8 (en) 2007-04-25
US20060211636A1 (en) 2006-09-21
IL156561A0 (en) 2004-01-04
NZ526450A (en) 2005-04-29
NO20032846D0 (no) 2003-06-20
AR042583A1 (es) 2005-06-29
NO20032846L (no) 2003-08-20
US20040077557A1 (en) 2004-04-22
MXPA03005668A (es) 2004-12-03
ES2275621T3 (es) 2007-06-16
AU1727702A (en) 2002-07-01
CN1492874A (zh) 2004-04-28
EP1363925B1 (en) 2006-11-15
BR0116431A (pt) 2004-06-22
EP1363925A1 (en) 2003-11-26
US20050215495A1 (en) 2005-09-29
ATE345350T1 (de) 2006-12-15
DE60124594T2 (de) 2007-10-04
CA2432429A1 (en) 2002-06-27
CZ20031751A3 (cs) 2004-03-17
JP2004531471A (ja) 2004-10-14
DE60124594D1 (de) 2006-12-28
AU2002217277B2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
AU1727702A (en) Macrolide antibiotics
AU2002217277A1 (en) Macrolide antibiotics
AU2001272719A1 (en) Macrolide antibiotics
IL144178A0 (en) Ketolide antibiotics
TWI318880B (en) Azalide antibiotic compositions
EP1311531A4 (en) ANTIBIOTICS DERIVED FROM STEROIDS
GB0127349D0 (en) Macrolides
HUP0104192A3 (en) Novel macrolide antibiotics
HUP0303935A3 (en) Ketolide antibacterial compounds
PL361276A1 (pl) Solwaty makrolidów
AU2002230386A1 (en) Sixteen-membered macrolide compounds
PL353770A1 (pl) Gen Streptomyces avermitilis decydujący o stosunkuGen Streptomyces avermitilis decydujący o stosunku awermektyn B1:B2 awermektyn B1:B2
PL353874A1 (pl) Gen Streptomyces avermitilis decydujący o stosunkuGen Streptomyces avermitilis decydujący o stosunku awermektyn B1:B2 awermektyn B1:B2
EP1289913A4 (en) NEW ANTIBIOTIC COMPOUNDS
GB0031314D0 (en) Macrolides
GB0025691D0 (en) Macrolides
GB0025687D0 (en) Macrolides
GB0025683D0 (en) Macrolides
GB0031313D0 (en) Macrolides
GB0025685D0 (en) Macrolides
GB0025689D0 (en) Macrolides
GB0031306D0 (en) Macrolides
GB0031309D0 (en) Macrolides
GB0031311D0 (en) Macrolides
AU5806101A (en) Novel antibiotic compounds

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)